<DOC>
	<DOCNO>NCT02260050</DOCNO>
	<brief_summary>To establish bioequivalence new formulation WAL 801 CL dry syrup vs. conventional formulation WAL 801 CL dry syrup</brief_summary>
	<brief_title>Bioequivalence New Formulation WAL 801 CL Dry Syrup Compared Conventional Formulation WAL 801 CL Dry Syrup Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Epinastine</mesh_term>
	<criteria>Healthy male accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( blood pressure ( BP ) , pulse rate ( PR ) , body temperature ( BT ) ) , 12lead ECG , clinical laboratory test ( include gastric acidity ( GA ) test ) No find clinical relevance No evidence clinically relevant concomitant disease Age ≥ 20 Age ≤ 35 year BMI ≥ 18.5 BMI ≤ 25 kg/m2 ( Body Mass Index ) Signed date write informed consent prior Screening Phase prior Treatment Phase ( Day 1 Treatment period 1 ) accordance Japanese Good Clinical Practice ( GCP ) Current gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder History surgery gastrointestinal tract exception appendectomy History ( and/or current ) diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Current chronic relevant acute infection History hypersensitivity ( include drug allergy ) current allergic disorder deem relevant trial investigator subinvestigators ; e.g . bronchial asthma , allergic rhinitis , atopic dermatitis food allergy ( exclude asymptomatic seasonal rhinitis/hay fever ) Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior drug administration Treatment Phase Use drug might reasonably influence result trial base knowledge time protocol preparation , within 10 day prior administration Treatment Phase Participation Phase I trial new chemical entity within 4 month prior drug administration trial , another clinical trial within 3 month prior drug administration Treatment Phase Smoker ( 10 cigarette 3 cigar 3 pipes/day ) Inability refrain smoke hospitalization Alcohol abuse ( 60 g/day ) ( confirm interview ) Drug abuse ( confirm interview ) Whole blood donation ( 400 mL within 3 month 100 mL within 4 week prior drug administration trial ) component blood donation ( within 2 week prior drug administration Treatment Phase ) Excessive physical activity ( within 48 hour prior treatment period hospitalisation ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen study centre</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>